Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Monday, December 24 through Wednesday, December 26 inclusive. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Citing this Article

Right click to copy or hit: ctrl+c (cmd+c on mac)

Published on 12.09.16 in Vol 5, No 3 (2016): Jul-Sept

This paper is in the following e-collection/theme issue:

Works citing "EXpanding Treatment for Existing Neurological Disease (EXTEND): An Open-Label Phase II Clinical Trial of Hydroxyurea Treatment in Sickle Cell Anemia"

According to Crossref, the following articles are citing this article (DOI 10.2196/resprot.5872):

(note that this is only a small subset of citations)

  1. Case M, Shirinpour S, Vijayakumar V, Zhang H, Datta Y, Nelson S, Pergami P, Darbari DS, Gupta K, He B. Graph theory analysis reveals how sickle cell disease impacts neural networks of patients with more severe disease. NeuroImage: Clinical 2018;
    CrossRef
  2. Smart LR, Hernandez AG, Ware RE. Sickle cell disease: Translating clinical care to low-resource countries through international research collaborations. Seminars in Hematology 2018;55(2):102
    CrossRef
  3. Marks LJ, Munube D, Kasirye P, Mupere E, Jin Z, LaRussa P, Idro R, Green NS. Stroke Prevalence in Children With Sickle Cell Disease in Sub-Saharan Africa: A Systematic Review and Meta-Analysis. Global Pediatric Health 2018;5:2333794X1877497
    CrossRef
  4. Brewin J, Kaya B, Chakravorty S. How I manage sickle cell patients with high transcranial doppler results. British Journal of Haematology 2017;179(3):377
    CrossRef
  5. Jeste ND, Sánchez LM, Urcuyo GS, Bergés ME, Luden JP, Stuber SE, Latham TS, Mena R, Nieves RM, Ware RE. Stroke Avoidance for Children in REpública Dominicana (SACRED): Protocol for a Prospective Study of Stroke Risk and Hydroxyurea Treatment in Sickle Cell Anemia. JMIR Research Protocols 2017;6(6):e107
    CrossRef